BBC · ARCA · ETF
Virtus Biotech Clinical Trials ETF (BBC) Price, Holdings & Fees
Virtus Biotech Clinical Trials ETF (BBC) closed at $324.36 on Oct 9, 2026, up 0.19% from the previous close of $323.73.
Share price, past year
1Y +1.33%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $324.36 |
| Sep 30, 2026 | $324.58 |
| Aug 31, 2026 | $330.58 |
| Jul 31, 2026 | $346.77 |
| Jun 30, 2026 | $332.82 |
| May 29, 2026 | $337.12 |
| Apr 30, 2026 | $332.48 |
| Mar 31, 2026 | $321.44 |
| Feb 27, 2026 | $321.72 |
| Jan 30, 2026 | $328.53 |
| Dec 31, 2025 | $331.32 |
| Nov 28, 2025 | $332.61 |
| Oct 31, 2025 | $338.09 |
Key statistics
- Expense ratio
- 0.65%
- as of Feb 28, 2026
- Net assets
- $46.4M
- as of Jul 31, 2026
- Holdings
- 132
- as of Jul 31, 2026
- 52-week range
- $318.44 – $352.22
Virtus Biotech Clinical Trials ETF's expense ratio is 0.65%: $65.00 a year on $10,000 invested.
Holdings
Virtus Biotech Clinical Trials ETF held 132 investments worth $46.39M as of Jul 31, 2026. Its largest holding was DREYFUS GOVERNMENT CASH MANAGE, at 3.48% of the fund.
| # | Holding | % of fund | Value |
|---|---|---|---|
| 1 | DREYFUS GOVERNMENT CASH MANAGE | 3.48% | $1.61M |
| 2 | FIRST TRACKS BIOTHERAPEUTICS INCTRAX | 1.67% | $775.98K |
| 3 | MBX BIOSCIENCES INCMBX | 1.24% | $577.15K |
| 4 | ATAIBECKLEY INC | 1.23% | $569.30K |
| 5 | MONOPAR THERAPEUTICS INCMNPR | 1.21% | $563.42K |
| 6 | DEFINIUM THERAPEUTICS INCDFTX | 1.18% | $546.52K |
| 7 | XENCOR INCXNCR | 1.10% | $509.45K |
| 8 | ZENAS BIOPHARMA INCZBIO | 1.06% | $493.51K |
| 9 | UNIQURE NVQURE | 1.06% | $491.84K |
| 10 | APOGEE THERAPEUTICS INC | 1.02% | $471.86K |
| 11 | VOR BIOPHARMA INCVOR | 0.99% | $457.77K |
| 12 | REGENXBIO INCRGNX | 0.97% | $452.23K |
| 13 | LB PHARMACEUTICALS INCLBRX | 0.94% | $438.31K |
| 14 | DAMORA THERAPEUTICS INCDMRA | 0.93% | $433.60K |
| 15 | AMYLYX PHARMACEUTICALS INCAMLX | 0.93% | $432.66K |
| 16 | DYNE THERAPEUTICS INCDYN | 0.93% | $430.25K |
| 17 | ORUKA THERAPEUTICS INCORKA | 0.93% | $429.18K |
| 18 | NURIX THERAPEUTICS INCNRIX | 0.92% | $425.60K |
| 19 | ORIC PHARMACEUTICALS INCORIC | 0.90% | $416.07K |
| 20 | GH RESEARCH PLCGHRS | 0.89% | $413.08K |
| 21 | SIONNA THERAPEUTICS INCSION | 0.88% | $407.82K |
| 22 | DIANTHUS THERAPEUTICS INCDNTH | 0.87% | $404.91K |
| 23 | ERASCA INCERAS | 0.87% | $401.51K |
| 24 | JADE BIOSCIENCES INCJBIO | 0.86% | $400.15K |
| 25 | SELLAS LIFE SCIENCES GROUP INCSLS | 0.86% | $397.35K |
Top 25 of 132 holdings, as of Jul 31, 2026. Percentages are of the fund's net assets.
What the fund owns
| Asset type | % of fund |
|---|---|
| Stocks | 99.84% |
| Cash and short-term investments | 3.48% |
| Country | % of fund |
|---|---|
| United States | 86.66% |
| Cayman Islands | 5.32% |
| Canada | 3.40% |
| Netherlands | 3.00% |
| Ireland | 1.55% |
| United Kingdom | 1.27% |
| British Virgin Islands | 0.80% |
| Switzerland | 0.68% |
| Singapore | 0.63% |
Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.
Monthly total returns
Over the 3 months to Jul 31, 2026, Virtus Biotech Clinical Trials ETF's total return was +11.18%, as reported to the SEC.
| Month | Total return |
|---|---|
| Jul 31, 2026 | −7.30% |
| Jun 30, 2026 | +18.04% |
| May 31, 2026 | +1.61% |
The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.
Fund profile
- Name
- Virtus Biotech Clinical Trials ETF
- Ticker
- BBC
- Exchange
- ARCA
- Fund type
- ETF
- Trust
- ETFis Series Trust I
- SEC series ID
- S000047353
- SEC CIK
- 0001559109
- Fractional shares
- Yes
Recent SEC filings
- Sep 29, 2026
- Oct 7, 2026
- 485BPOSProspectus updateJul 9, 2026
- Jul 2, 2026
- Apr 8, 2026
- 485BPOSProspectus updateFeb 27, 2026
- Jan 8, 2026
- 485BPOSProspectus updateNov 25, 2025
Shareholder reports and prospectuses are filed by ETFis Series Trust I, the trust behind Virtus Biotech Clinical Trials ETF, and cover all of its funds.
Frequently asked questions
What is BBC's price?
Virtus Biotech Clinical Trials ETF (BBC) closed at $324.36 on Oct 9, 2026, up 0.19% from the previous close of $323.73.
What is BBC's expense ratio?
Virtus Biotech Clinical Trials ETF's expense ratio is 0.65%: $65.00 a year on $10,000 invested.
What does BBC hold?
Virtus Biotech Clinical Trials ETF held 132 investments worth $46.39M as of Jul 31, 2026. Its largest holding was DREYFUS GOVERNMENT CASH MANAGE, at 3.48% of the fund. Its five largest holdings were DREYFUS GOVERNMENT CASH MANAGE, FIRST TRACKS BIOTHERAPEUTICS INC, MBX BIOSCIENCES INC, ATAIBECKLEY INC, MONOPAR THERAPEUTICS INC.
How has BBC performed?
Over the 3 months to Jul 31, 2026, Virtus Biotech Clinical Trials ETF's total return was +11.18%, as reported to the SEC.
Sources and methodology
Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jul 31, 2026 (filed Sep 29, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Feb 28, 2026. Prices are generated sample data for development. Data sources and disclosures